Not Signed In -
Ethosuximide Capsules |
Zarontin |
Clinical Trial: A Phase II Study of Tarceva and Targretin Oral Capsules in Patients with Advanced Advanced Lung Cancer
This study is not yet open for patient recruitment.
Verified by Dartmouth-Hitchcock Medical Center July 2005
|
Purpose
The purpose of this study is to learn the effects of two new anticancer drugs, erlotinib and bexarotene, when treating patients with advanced lung cancer. Erlotinib is approved by the FDA for the treatment of non-small cell lung cancer. Bexarotene is approved by the FDA for treatment of cutaneous T-cell lymphoma. This combination of drugs is experimental.
| Condition | Intervention | Phase |
|---|---|---|
| Carcinoma, Non-Small Cell Lung Cancer Non-small cell lung cancer NSCLC | Drug: erlotinib (drug) and bexarotene (drug) | Phase II |
MedlinePlus related topics: Lung Cancer
Study Type: Interventional
Study Design: Treatment, Non-Randomized, Open Label, Uncontrolled, Single Group Assignment, Efficacy Study
Official Title: A Phase II Clinical Study of Erlotinib (Tarceva) and Bexarotene (Targretin) Oral Capsules in Patients with Advanced Non-Small Cell Lung Cancer
Further Study Details:
Primary Outcomes: response rates; progression free survival; overall survival
Expected Total Enrollment: 40
Expected Total Enrollment: 40
Study start: August 2005
Eligibility
Ages Eligible for Study: 18 Years and above, Genders Eligible for Study: Both
Criteria
Inclusion Criteria:
- advanced NSCLC
- prior chemotherapy or radiotherapy is allowed
Exclusion Criteria:
- hepatic or renal dysfunction
Location and Contact Information
Please refer to this study by ClinicalTrials.gov identifier NCT00125359
Konstantin H Dragnev, MD 603-650-6344 Konstantin.H.Dragnev@Dartmouth.edu
Ian R Williams, BA 603-650-6056 ian.r.williams@dartmouth.edu
Ian R Williams, BA 603-650-6056 ian.r.williams@dartmouth.edu
Study chairs or principal investigators
Konstantin H Dragnev, MD, Principal Investigator, Norris Cotton Cancer Center
More Information
Study ID Numbers: D-0440
Last Updated: August 1, 2005
Record first received: July 29, 2005
ClinicalTrials.gov Identifier: NCT00125359
Health Authority: United States: Food and Drug Administration
ClinicalTrials.gov processed this record on 2005-08-02
Last Updated: August 1, 2005
Record first received: July 29, 2005
ClinicalTrials.gov Identifier: NCT00125359
Health Authority: United States: Food and Drug Administration
ClinicalTrials.gov processed this record on 2005-08-02
Resources
- Ethosuximide Capsules (Drug Digest)
- Zarontin (Drug Digest)
email this page
print this page
bookmark this page
feedback on this page
